Mineralys Therapeutics, Inc. MLYS Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s investing cash flow?
- Mineralys Therapeutics, Inc. (MLYS) reported investing cash flow of -$44.94M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Mineralys Therapeutics, Inc.'s investing cash flow increased by 51.6% year-over-year, from -$92.88M to -$44.94M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s investing cash flow?
- Over 2 years (2023 to 2025), Mineralys Therapeutics, Inc.'s investing cash flow has grown at a 53.9% compound annual growth rate (CAGR), from -$164.48M to -$389.75M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.